netbook
desktop
mobile
tablet-landscape
tablet
phone-landscape
phone
Research to Prevent Blindness

AMD Drug Can Prevent Vision Loss in Diabetics With Diabetic Macular Edema

RPB-supported researchers at the University of Southern California (USC) report that ranibizumab (sold as Lucentis) can help Hispanic and non-Hispanic whites with diabetic macular edema (DME) in the United States avoid visual impairment and blindness.  Diabetic retinopathy and DME are the leading causes of vision loss in working-age adults in the United States.

Read the story on the USC's website

Read the research in Ophthalmology

Related News: Top Story

RPB logo

Research to Prevent Blindness Announces New Sight-Saving Vision Research Grants

RPB launches awards in data science and Diabetic Eye Disease.

Read More

 
RPB Logo

Vision Research Funding Partnership Event Takes Place Today

Leaders of organizations that fund vision research convene in Washington DC to increase collaboration and maximize the impact of research funding for sight-threatening diseases.

Read More

 
Dr. Raj Apte

Understanding Corneal Injuries in Dry Eyes

An RPB grantee makes a key discovery involving genes that are essential for eye health.

Read More

 
RPB logo

Research to Prevent Blindness Marks $400 Million in Funding to Advance Eye Disease Research

RPB funds a new round of researchers and hits a milestone in supporting vision-related breakthroughs.

Read More

 
Giving Tuesday logo

RPB Supporters Save Sight on Giving Tuesday

We welcome your generosity to help us meet our goal!

Read More

 
Dr. Palczewski and lab members

An RPB Awardee Tackles Inherited Retinal Diseases

Dr. Krzysztof Palczewski develops and applies cutting-edge gene editing techniques to challenging genetic conditions.

Read More

 

Subscribe

Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.